VC-backed Selecta Biosciences debuts IPO
Watertown, Massachusetts-based Selecta Biosciences, a clinical stage biotech company, has raised $70 million for its IPO after pricing its 5 million shares at $14 per share. The stock began trading June 22, 2016 on the NASDAQ under the ticker symbol "SELB." UBS Investment Bank and Stifel are the lead underwriters. Selecta Biosciences' backers included OrbiMed, Sanofi-Genzyme BioVentures, Ridgeback Capital Management, Osage University Partners, AJU IB Investment and Sphera Global Health Care Fund.
22 June 2016•2 mins read
